|
시장보고서
상품코드
2078890
우울증 치료제 시장 : 약제 유형별, 적응증별, 유통 채널별 및 지역별Depression Therapeutics Market, By Drug Type, By Indication, By Distribution Channel, and By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
우울증 치료제 시장은 2026년에 147억 5,000만 달러, 2033년까지 203억 5,000만 달러에 이를 것으로 예상됩니다. 또한, 2026-2033년 CAGR 4.7%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 147억 5,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 4.70% | 2033년 시장 규모 예측 : | 203억 5,000만 달러 |
우울증은 전 세계 여러 지역, 특히 도시 지역에서 “침묵의 살인자”로 떠오르고 있습니다. 우울증의 유병률은 계속해서 급속히 증가하고 있으며, 사망률과 발병률도 상당히 높기 때문에 의료 업계에서는 새로운 약물과 치료법의 개발이 지속적으로 진행되고 있습니다. 항우울제는 주요 우울증이나 불안 장애 등 중증에서 경증에 이르는 정신 질환에 처방됩니다. 이러한 질환의 치료에 있어 대체할 수 있는 약물 요법이 제한적이기 때문에 항우울제 시장은 매우 수익성이 높은 분야로 자리 잡고 있습니다. 각 제약사는 선택적 세로토닌 재흡수 억제제(SSRI)나 선택적 노르에피네프린 재흡수 억제제(SNRI)와 같은 혁신적인 치료법을 도입함으로써 항우울제 분야를 더욱 발전시키고 있습니다. 우울증은 가장 흔한 정신 질환 중 하나이며, 주로 항우울제로 치료됩니다. 영국 국민보건서비스 디지털(NHS Digital)에 따르면, 2016년에는 항우울제 처방 건수가 가장 크게 증가했습니다.
시장 역학
세계 우울증 치료제 시장은 대체 요법의 부재와 시장에서 제네릭 의약품 제조업체들의 강력한 입지 등 여러 요인에 힘입어 성장하고 있습니다. 주요 의약품의 상당수가 특허 보호 기간이 만료됨에 따라, 제네릭 의약품 제조업체들의 제품 라인업 개발이 증가하고 있으며, 이것이 시장 성장을 뒷받침하고 있습니다. 이러한 의약품이 치료 효과 향상에 효과적임이 입증된 점과, 우울증 등의 질환 유병률 증가가 시장 성장을 가속하고 있습니다.
예를 들어, 알러간(Allergan Plc.)이 제조하는 ‘페치마(Fetzima)'는 3건의 특허로 보호받고 있으며, 이 특허들은 각각 2031년, 2033년, 2023년에 만료될 전망입니다.
그러나, 포장지에 기재된 블랙박스 경고에서 알 수 있듯이, 이러한 약물에 수반되는 생명을 위협하는 부작용과 주요 기업들의 연구 개발 부족이 우울증 치료제 시장의 성장을 저해할 것으로 예측됩니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
- 본 조사에서는 다음의 매개변수를 바탕으로 전 세계 항우울제 시장의 주요 기업 프로파일을 작성하고 있습니다. 구체적으로는 기업 개요, 재무 실적, 제품 포트폴리오, 시장 내 입지, 유통 전략, 주요 발전 사항, 전략 및 향후 계획입니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 유형 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- "세계의 우울증 치료제 시장 보고서”는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 항우울제 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 우울증 치료제 시장 : 약제 유형별, 2021년-2033년
제5장 세계의 우울증 치료제 시장 : 적응증별, 2021년-2033년
제6장 세계의 우울증 치료제 시장 : 유통 채널별, 2021년-2033년
제7장 세계의 우울증 치료제 시장 : 지역별, 2021년-2033년
제8장 경쟁 구도
제9장 섹션
LSH 26.07.10Depression Therapeutics Market is estimated to be valued at USD 14.75 Bn in 2026 and is expected to reach USD 20.35 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 14.75 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.70% | 2033 Value Projection: | USD 20.35 Bn |
Depression has emerged as a 'silent killer' in several regions across the world, particularly in urban cities. The prevalence of depression continues to grow rapidly with considerably high mortality and morbidity rate due to which, the healthcare sector continues its pursuit of novel medications and therapies. Antidepressants are prescribed in serious to mild mental health conditions such as major depression and anxiety. Antidepressant drug category is highly lucrative due to low availability of alternative drug therapies for the treatment of such disorders. Drug manufacturers are increasingly advancing the antidepressant drug category by introducing innovative therapies such as selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs). Depression is one of the most common mental disorders, which are primarily treated by antidepressants. According to National Health Service Digital (NHS Digital), UK, antidepressant medication prescription observed the largest increase in 2016.
Market Dynamics
The global depression drugs market is driven by factors such as absence of alternative therapies and high presence of generic drug manufacturers in the market. Increasing number of major drugs are losing patent protection due to which increasing number of generic manufacturers are developing product variations, which in turn is boosting the growth of the market. Proven effectiveness of these medications in improving medical outcomes and increasing prevalence of disorders such as depression are fueling growth of the market.
For instance, Fetzima, manufactured by Allergan Plc., is protected by three patents, which are expected to expire in 2031, 2033, and 2023.
However, life threatening side effects associated with these medications as indicated by the black box warning on the packaging, as well as lack of research and development by major players are expected to hinder growth of the depression drugs market.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global depression drugs market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Merck & Co., Inc., GlaxoSmithKline plc, AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Johnson & Johnson, Sanofi S.A., Pfizer, Inc., Allergan plc, H. Lundbeck A/S, and Alkermes
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global depression drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global depression drugs market
Detailed Segmentation:
- Global Depression Drugs Market, By Drug Type (Revenue, USD Bn, 2021 - 2033)
- Antidepressants
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin Norepinephrine Reuptake Inhibitor (SNRIs)
- Serotonin Modulators
- Tricyclic & Tetracyclic Antidepressants
- Atypical Antidepressants
- Antipsychotics
- Others (CNS Stimulants, Monoamine Oxidase Inhibitors)
- Global Depression Drugs Market, By Indication:
- Major Depressive Disorder (MDD)
- Bipolar Disorder
- Dysthymic Disorder
- Postpartum Depression
- Seasonal Affective Disorder (SAD)
- Premenstrual Dysphoric Disorder (PMDD)
- Others
- Global Depression Drugs Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Depression Drugs Market, By Region (Revenue, USD Bn, 2021 - 2033)
- North America
- By Drug Type
- Antidepressants
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin Norepinephrine Reuptake Inhibitor (SNRIs)
- Serotonin Modulators
- Tricyclic & Tetracyclic Antidepressants
- Atypical Antidepressants
- Antipsychotics
- Others (CNS Stimulants, Monoamine Oxidase Inhibitors)
- Antidepressants
- By Indication
- Major Depressive Disorder (MDD)
- Bipolar Disorder
- Dysthymic Disorder
- Postpartum Depression
- Seasonal Affective Disorder (SAD)
- Premenstrual Dysphoric Disorder (PMDD)
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- U.S.
- Canada
- By Drug Type
- Latin America
- By Drug Type
- Antidepressants
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin Norepinephrine Reuptake Inhibitor (SNRIs)
- Serotonin Modulators
- Tricyclic & Tetracyclic Antidepressants
- Atypical Antidepressants
- Antipsychotics
- Others (CNS Stimulants, Monoamine Oxidase Inhibitors)
- Antidepressants
- By Indication
- Major Depressive Disorder (MDD)
- Bipolar Disorder
- Dysthymic Disorder
- Postpartum Depression
- Seasonal Affective Disorder (SAD)
- Premenstrual Dysphoric Disorder (PMDD)
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Drug Type
- Europe
- By Drug Type
- Antidepressants
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin Norepinephrine Reuptake Inhibitor (SNRIs)
- Serotonin Modulators
- Tricyclic & Tetracyclic Antidepressants
- Atypical Antidepressants
- Antipsychotics
- Others (CNS Stimulants, Monoamine Oxidase Inhibitors)
- Antidepressants
- By Indication
- Major Depressive Disorder (MDD)
- Bipolar Disorder
- Dysthymic Disorder
- Postpartum Depression
- Seasonal Affective Disorder (SAD)
- Premenstrual Dysphoric Disorder (PMDD)
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Drug Type
- Asia Pacific
- By Drug Type
- Antidepressants
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin Norepinephrine Reuptake Inhibitor (SNRIs)
- Serotonin Modulators
- Tricyclic & Tetracyclic Antidepressants
- Atypical Antidepressants
- Antipsychotics
- Others (CNS Stimulants, Monoamine Oxidase Inhibitors)
- Antidepressants
- By Indication
- Major Depressive Disorder (MDD)
- Bipolar Disorder
- Dysthymic Disorder
- Postpartum Depression
- Seasonal Affective Disorder (SAD)
- Premenstrual Dysphoric Disorder (PMDD)
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Drug Type
- Middle East
- By Drug Type
- Antidepressants
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin Norepinephrine Reuptake Inhibitor (SNRIs)
- Serotonin Modulators
- Tricyclic & Tetracyclic Antidepressants
- Atypical Antidepressants
- Antipsychotics
- Others (CNS Stimulants, Monoamine Oxidase Inhibitors)
- Antidepressants
- By Indication
- Major Depressive Disorder (MDD)
- Bipolar Disorder
- Dysthymic Disorder
- Postpartum Depression
- Seasonal Affective Disorder (SAD)
- Premenstrual Dysphoric Disorder (PMDD)
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- By Drug Type
- Africa
- By Drug Type
- Antidepressants
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin Norepinephrine Reuptake Inhibitor (SNRIs)
- Serotonin Modulators
- Tricyclic & Tetracyclic Antidepressants
- Atypical Antidepressants
- Antipsychotics
- Others (CNS Stimulants, Monoamine Oxidase Inhibitors)
- Antidepressants
- By Indication
- Major Depressive Disorder (MDD)
- Bipolar Disorder
- Dysthymic Disorder
- Postpartum Depression
- Seasonal Affective Disorder (SAD)
- Premenstrual Dysphoric Disorder (PMDD)
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region
- South Africa
- Central Africa
- North Africa
- By Drug Type
- Company Profiles
- Merck & Co., Inc.*
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- GlaxoSmithKline plc
- AstraZeneca Plc
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Johnson & Johnson
- Sanofi S.A.
- Pfizer, Inc.
- Allergan plc
- Lundbeck A/S
- Alkermes
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Drug Launches
- Epidemiology
- Pipeline Analysis
- Distribution Landscape
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Depression Therapeutics Market, By Drug Type, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Selective Norepinephrine Reuptake Inhibitors (SNRIs)
- Serotonin Modulators
- Tricyclic & Tetracyclic Antidepressants
- Atypical Antidepressants
- Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
5. Global Depression Therapeutics Market, By Indication, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Major Depressive Disorder (MDD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Bipolar Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Dysthymic Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Postpartum Depression
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Seasonal Affective Disorder (SAD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Premenstrual Dysphoric Disorder (PMDD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
6. Global Depression Therapeutics Market, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
7. Global Depression Therapeutics Market, By Region, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/ Region, 2021 -2033, (US$ Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Company Profiles
- Johnson & Johnson
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- GlaxoSmithKline plc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Takeda Pharmaceutical Company Limited.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Sanofi S.A.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Allergan plc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- H. Lundbeck A/S
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Alkermes
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Allergan
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Biogen
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Sage Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Johnson & Johnson
9. Section
- References
- Research Methodology
- About us and Sales Contact
